[
  {
    "item_id": "press_corporate__nanexa_20251223_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "PRESSRELEASES10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE6 November, 2025Nanexa publishes interim report for January-September 2025We have progresse",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:a6f60bd2b0d446163f5bee10d1c134f77d3228b27e0b3e62cef64f33d4208a2d",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 71
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251223_6f822c",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products",
    "content": "10 December, 2025Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based productsThe agreement covers the development of up to five undisclosed compounds. Nanexa will receive an upfront payment of USD 3 million and is entitled to up to USD 500 million in potential milestone payments as well as a tiered single-digit royalty on product sales.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-and-moderna-enter-into-license-and-option-agreement-for-the-development-of-pharmashell-based-products/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:d9b83fe6cb94dcaa8e1245f54fd2e589b6cf48151c4b60378d8012a5e5a20125",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 61
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251223_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025We have progressed with the optimization of our GLP-1 formulations, extended an existing commercial partnership, received approval for a PharmaShell patent application in Japan and submitted three new patent applications.READ MORE",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:0ae524c2c1742348fd5891a0d63556633a6fe131dc6d0a64705a3620d73771c9",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 39
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251223_ec88d7",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-September 2025",
    "content": "6 November, 2025Nanexa publishes interim report for January-September 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-september-2025/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:5e92a34fa02feb0c756160060d140bd43be564d228173af1a7475fc55abd2012",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251223_e8d104",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Download attachment",
    "content": "Download attachment",
    "url": "https://storage.mfn.se/ab91ff14-4c8b-4c40-85a9-996052a19950/nanexa-interim-report-january-september-2025.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:3d03c0ba4af110790f2466800ad3cb177d90875ff5aca390550800cb8fb5b287",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 2
    }
  },
  {
    "item_id": "press_corporate__nanexa_20251223_76ad60",
    "source_key": "press_corporate__nanexa",
    "source_type": "press_corporate",
    "title": "Nanexa publishes interim report for January-June 2025",
    "content": "27 August, 2025Nanexa publishes interim report for January-June 2025Download attachment",
    "url": "https://nanexa.com/mfn_news/nanexa-publishes-interim-report-for-january-june-2025/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:32.073225",
    "language": "en",
    "content_hash": "sha256:5ebaa7e082a1cf6d1df5f67bacd000c99e99c281c9cc7c0d2499114067d696b3",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 10
    }
  },
  {
    "item_id": "press_corporate__delsitech_20251223_e3d7ad",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28",
    "content": "Partnership Opportunities in Drug Delivery 2025 Boston, October 27-28Essi Nevo2025-08-15T11:33:54+02:00August 15th, 2025|Read More",
    "url": "https://www.delsitech.com/partnership-opportunities-in-drug-delivery-2025-boston-october-27-28/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:35.422661",
    "language": "en",
    "content_hash": "sha256:9362998c5af4ef533152f4c2d2f7f2a5a831f17fb5c84d2e9918492eabf312d7",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 13
    }
  },
  {
    "item_id": "press_corporate__delsitech_20251223_ad0afc",
    "source_key": "press_corporate__delsitech",
    "source_type": "press_corporate",
    "title": "BIO International Convention 2025 Boston, June 16-19",
    "content": "BIO International Convention 2025 Boston, June 16-19Aleksi Leino2025-06-12T15:59:56+02:00June 12th, 2025|Read More",
    "url": "https://www.delsitech.com/bio-international-convention-2025-boston-june-16-19/",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:35.422661",
    "language": "en",
    "content_hash": "sha256:57720ff336bac6a3ca5237373c94baaa3eec122461772429e7c57553296abdcf",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_2b08cd",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)",
    "content": "Medincell Publishes its Consolidated Half-Year Financial Results (April 1st , 2025 – September 30, 2025)December 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_HY-Results-EN_09122025-1.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:d31f0b2539d43d16674e54130adf76dadd16de4d64da01b46089ef7d05087f56",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 19
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_516562",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in Adults",
    "content": "Medincell’s Partner Teva Pharmaceuticals Announces the New Drug Application Submission to U.S. FDA for Olanzapine Extended-Release Injectable Suspension (TEV-‘749 / mdc-TJK) for the Once-Monthly Treatment of Schizophrenia in AdultsDecember 9, 2025December 9, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/12/MDC_Olanzapine-NDA-filing_09122025_EN_vf-2.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:c2ed94aa0c2dfe5546577b2452e9dc35255e76491c079fb1906d579722fa5fd2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 33
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_150759",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Awarded New Grant to Fight Malaria",
    "content": "Medincell Awarded New Grant to Fight MalariaNovember 24, 2025November 24, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_Gates-Malaria_PR_24112025_vf.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:2077438074167cf84530cd63f435d4d32c7966446ec74b1d2d88da3c63b8e447",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 11
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_63c5d2",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital Growth",
    "content": "Medincell Appoints Dr Grace Kim, Chief Strategy Officer, U.S. Finance, to Advance into Next Stage of US Capital GrowthNovember 11, 2025November 11, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_G_KIM_10112025_EN_vf.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:0fd65830bac79a1367fb57ebdb608040c3d60da28c61faceaa909e7a158b29f2",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 23
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_846e38",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "Medincell to Join MSCI World Small Cap Index, a Leading Global Benchmark",
    "content": "Medincell to Join MSCI World Small Cap Index, a Leading Global BenchmarkNovember 10, 2025November 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/MDC_MSCI-Small-Index_10112025_EN_vf.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:56a3453e4ee40153ae56677367b25aa29f62e6fdeeba03e4c9c8d2f2706a1923",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 16
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_c147c4",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025",
    "content": "UZEDY® continues strong growth; Teva setting the stage for US NDA Submission for Olanzapine LAI in Q4 2025November 5, 2025November 5, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/11/PR_MDC_Teva-earnings-Q3_2025_05112025_vf.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:7f3a6a00314b234fd43355bd5206916bed56d46d3f812a774fb1cbb61c28ec28",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 22
    }
  },
  {
    "item_id": "press_corporate__medincell_20251223_1781cc",
    "source_key": "press_corporate__medincell",
    "source_type": "press_corporate",
    "title": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I Disorder",
    "content": "FDA Approves Expanded Indication for UZEDY® (risperidone) Extended-Release Injectable Suspension as a Treatment for Adults Living with Bipolar I DisorderOctober 10, 2025October 10, 2025",
    "url": "https://www.medincell.com/wp-content/uploads/2025/10/MDC_UZEDY-BDI_EN_10102025_vf.pdf",
    "published_at": "2025-12-23",
    "ingested_at": "2025-12-23T07:23:38.646059",
    "language": "en",
    "content_hash": "sha256:9af83ff908da116aea79f158b3ebdf544ae2c357adfb5de082941c5913f41ffb",
    "metadata": {
      "author": "",
      "tags": [],
      "word_count": 24
    }
  }
]